153 related articles for article (PubMed ID: 34711619)
1. Non-tuberculous mycobacteria infection treated with intermittently inhaled high-dose nitric oxide.
Goldbart A; Gatt D; Golan Tripto I
BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34711619
[No Abstract] [Full Text] [Related]
2. Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection.
Bentur L; Gur M; Ashkenazi M; Livnat-Levanon G; Mizrahi M; Tal A; Ghaffari A; Geffen Y; Aviram M; Efrati O
J Cyst Fibros; 2020 Mar; 19(2):225-231. PubMed ID: 31129068
[TBL] [Abstract][Full Text] [Related]
3. Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients.
Yaacoby-Bianu K; Gur M; Toukan Y; Nir V; Hakim F; Geffen Y; Bentur L
Pediatr Infect Dis J; 2018 Apr; 37(4):336-338. PubMed ID: 28885458
[TBL] [Abstract][Full Text] [Related]
4. IgA Serological Response for the Diagnosis of Mycobacterium abscessus Infections in Patients with Cystic Fibrosis.
Le Moigne V; Roux AL; Mahoudo H; Christien G; Ferroni A; Dumitrescu O; Lina G; Bouchara JP; Plésiat P; Gaillard JL; Canaan S; Héry-Arnaud G; Herrmann JL
Microbiol Spectr; 2022 Jun; 10(3):e0019222. PubMed ID: 35583329
[TBL] [Abstract][Full Text] [Related]
5. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report.
Addy C; Doran G; Jones AL; Wright G; Caskey S; Downey DG
BMC Pulm Med; 2018 Nov; 18(1):170. PubMed ID: 30453935
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD010004. PubMed ID: 32521055
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide-releasing prodrug for the treatment of complex
McDonald RA; Nagy SG; Chambers M; Broberg CA; Ahonen MJR; Schoenfisch MH
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0132723. PubMed ID: 38206003
[TBL] [Abstract][Full Text] [Related]
8.
Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
[TBL] [Abstract][Full Text] [Related]
9. Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria.
Das S; Garg T; Chopra S; Dasgupta A
J Antimicrob Chemother; 2019 May; 74(5):1317-1322. PubMed ID: 30753528
[TBL] [Abstract][Full Text] [Related]
10. Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Martiniano SL; Wagner BD; Levin A; Nick JA; Sagel SD; Daley CL
Chest; 2017 Oct; 152(4):800-809. PubMed ID: 28483608
[TBL] [Abstract][Full Text] [Related]
11. Clinical aspects of the Mycobacterium abscessus complexAuthors' replyClinical aspects in patients with pulmonary infection caused by mycobacteria of the Mycobacterium abscessus complex, in the Brazilian AmazonBurden of non-tuberculous mycobacterial pulmonary disease in GermanyBritish Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
Joob B; Wiwanitkit V
J Bras Pneumol; 2018; 44(5):434-435. PubMed ID: 30517343
[No Abstract] [Full Text] [Related]
12. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.
Johansen MD; Herrmann JL; Kremer L
Nat Rev Microbiol; 2020 Jul; 18(7):392-407. PubMed ID: 32086501
[TBL] [Abstract][Full Text] [Related]
13. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
Shin SH; Jhun BW; Kim SY; Choe J; Jeon K; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104265
[No Abstract] [Full Text] [Related]
14. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.
Burke A; Smith D; Coulter C; Bell SC; Thomson R; Roberts JA
Clin Pharmacokinet; 2021 Sep; 60(9):1081-1102. PubMed ID: 33982266
[TBL] [Abstract][Full Text] [Related]
15. Nontuberculous mycobacterial infections in cystic fibrosis.
Martiniano SL; Nick JA
Clin Chest Med; 2015 Mar; 36(1):101-15. PubMed ID: 25676523
[TBL] [Abstract][Full Text] [Related]
16. Description of wylie-stanley agar for the recovery of
Moore JE; Murphy A; Millar BC
Int J Mycobacteriol; 2021; 10(2):166-169. PubMed ID: 34558469
[TBL] [Abstract][Full Text] [Related]
17. Serological biomarkers for the diagnosis of Mycobacterium abscessus infections in cystic fibrosis patients.
Le Moigne V; Roux AL; Mahoudo H; Christien G; Ferroni A; Dumitrescu O; Lina G; Bouchara JP; Plésiat P; Gaillard JL; Canaan S; Héry-Arnaud G; Herrmann JL
J Cyst Fibros; 2022 Mar; 21(2):353-360. PubMed ID: 34511392
[TBL] [Abstract][Full Text] [Related]
18. Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection.
Flume PA; Garcia BA; Wilson D; Steed L; Dorman SE; Winthrop K
Respir Med; 2023 Jan; 206():107069. PubMed ID: 36493605
[TBL] [Abstract][Full Text] [Related]
19. Disease caused by non-tuberculous mycobacteria in children with cystic fibrosis.
Lu M; Saddi V; Britton PN; Selvadurai H; Robinson PD; Pandit C; Marais BJ; Fitzgerald DA
Paediatr Respir Rev; 2019 Feb; 29():42-52. PubMed ID: 30473423
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and importance of non-tuberculous mycobacteria in adult patients with cystic fibrosis in a hospital in Madrid.
Fernández-Caso B; Vázquez R; Alarcón T; Girón R; López-Giménez MR; Domingo D
Enferm Infecc Microbiol Clin (Engl Ed); 2020; 38(7):323-326. PubMed ID: 31744623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
